

1789 TT

ScinoPharm

November 10, 2021



Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. ("ScinoPharm").

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation **is** ScinoPharm's **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company as to, the accuracy or completeness of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words "believes", "anticipates", "plans", "expects" and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management's plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from those implied by such forward-looking statements.



Table of Content

Business Update

Financial Performance





Business Update




Optimize Generic API Portfolio

Generic API Business Update

- Leverage Tainan/Changshu production advantage and strengthen sales/production coordination
- The impact of Covid-19 pandemic and dual control of energy consumption in China are still manageable

Generic API Portfolio



ScinoPharm

5

Optimize Generic API Portfolio

2021 Generic API Product Approval Plan


Туре	Product	Region	Indication	Brand Marketer
Generic API	Fondaparinux Sodium	CN(🗸)	Anti-thrombotic	Mylan
Generic API	Irinotecan HCI	CN	Colorectal cancer	Pfizer
Generic API	Anastrozole	CN	Breast cancer	ANI Pharmaceuticals
Generic API	Sodium Phenylbutyrate	CN(🗸)	Urea cycle disorders	Horizon Therapeutics
Generic API	Azilsartan	CN	Hypertension	Arbor Pharmaceuticals
Generic API	Letrozole	CN(🗸)	Breast cancer	Novartis
Generic API	Bimatoprost	CN	Glaucoma	Allergan
Generic API	Regadenoaon	US	MPI	Astellas
Generic API	* Pemetrexed Disodium 7H ₂ O CEP	EU	Non-small cell lung cancer	Eli Lilly
Generic API	Topiramate	EU	Weight management	Vivus

Substitution : Collaborative project for drug product development Data as of 2021/09/30



Expand CDMO Business

CDMO Business



Data as of 2021/09/30



Expand CDMO Business

2021 CDMO API Product Approval Plan

Туре	Product	Region	Indication	Brand Marketer
CDMO API	Donafenib	CN(🗸)	Cancer	Suzhou Zelgen
CDMO API	Camcevi	US(✔) EU	Cancer	Foresee
CDMO API	Eflornithine	US/EU	FAP	СРР

Data as of 2021/09/30


Donafenib:

- □ Approved and launched in China in June, 2021
 - (Indication: Advanced liver cancer)
- □ Summited to NMPA in Oct. 2021 (Indication: RAIR-DTC)

Camcevi:

- □ Approved by FDA in May, 2021; MAA review in progress
- □ Replied Canada Healthcare in Sep. 2021
- Eflornithine:
 - Submitted to FDA and EMA by customer









Pen Injectors

- **Registration batches of Vial line (prefilled-syringed /pen device)** and Cartridge line (liquid solution/ lyophilized powder) products were completed
 - ANDA of 1st in-house prefilled-syringe product was submitted to FDA in May, 2020 - Responded to FDA CRL in Sep. 2021
 - ANDA of 1st in-house liquid solution product was submitted to FDA in June, 2021 – FDA's review in progress
 - **Registration batches of 2nd prefilled-syringed product in progress**
 - Target to summit the ANDA of 1st in-house lyophilized powder product to FDA in year-end of 2021
- Completed the 1st TFDA on-site inspection in April, 2021 - Replied TFDA in Q3, 2021, and TFDA's review in progress



Actively Develop Japan, China and Emerging Markets

Japan Market

- Completed the establishment of Japan branch in Q3, 2021 to cultivate Japan market
- The largest generic API supplier for Galantamine HBr and Capecitabine in Japan
 - Indication : Alzheimer's disease / Various cancers
 - Japan market size : c. USD 200 million / over USD 100 million
- Leverage Japan's late patent expiration and our new injectables capacity to explore opportunities for generic APIs + CDMO projects



Actively Develop Japan, China and Emerging Markets

China Market

Customer's Fondaparinux Sodium PFS launched in Feb. 2021

- Indication : Anti-thrombotic
- □ Market Size : c. RMB 200 million

CFDI on-site inspection in Changshu site

Inspection	Product	Approval	Indication	Market
2020.09	Sodium Phenylbutyrate	2021.05	Urea cycle disorders	Urea cycle disorders
2021.02	Donafenib	2021.06	Advanced liver cancer first-line treatment	1 st year sales projected by research report : c. RMB 220 million
2021.06	Bimatoprost	Expected by 2021 year-end	Glaucoma	c. RMB 1 billion

- Clinic trial of customer's Sodium Phenylbutyrate for new indication in progress
- Customer's Donafenib summited to NMPA in Oct. 2021 for new indication RAIR-DTC





Financial Performance




Consolidated Income Statement

In NTD Million, except for EPS	3Q 2021 (Reviewed)		ΥοΥ	3Q 20 (Review	
Revenue	2,043	100%	-8%	2,209	100%
Gross Profit	945	46%	-11%	1,058	48%
Operating Profit	227	11%	-36%	354	16%
Net Profit before Tax	235	11%	-32%	346	16%
Net Profit after Tax	190	9%	-31%	274	12%
EPS (NTD)	0.24	-	-	0.35	-



3Q 2021 Sales Distribution



14

Sales Distribution – YoY

By Business

Unit: USD

	Generic API	CDMO	Drug Product
3Q 2021 Sales	55.2M	10.4M	7.3M
YoY	3.4%	-39.4%	105.3%

By Indication

	Oncology	CNS	Others
3Q 2021 Sales	50.6M	17.6M	4.7M
YoY	5.6%	-16.0%	-10.4%

By Region

	US & Canada	EU	Japan	India	China	Others
3Q 2021 Sales	18.4M	17.6M	20.8M	5.3M	4.8M	6.0M
ΥοΥ	27.1%	-42.1%	71.7%	-46.7%	125.7%	17.0%



Consolidated Balance Sheet

In NTD Million	2021/9/30 (Reviewed)		2020/9/30 (Reviewed)	
Cash and Cash Equivalents	3,732	33%	3,759	31%
Accounts Receivable	284	2%	468	4%
Inventories	1,373	12%	1,350	11%
Property, Plant & Equipment	4,066	36%	4,211	35%
Other Current/Non-Current Assets	1,994	17%	2,212	19%
Total Assets	11,449	100%	12,000	100%
Financial Debt	0	0%	244	2%
Other Current Liabilities	503	4%	638	6%
Other Non-Current Liabilities	624	6%	633	5%
Total Liabilities	1,127	10%	1,515	13%
Total Shareholders' Equities	10,322	90%	10,485	87%



Consolidated Cash Flow Statement

In NTD million	3Q 2021 (Reviewed)	3Q 2020 (Reviewed)
From Operating Activities	331	616
From Investing Activities	(238)	51
From Financing Activities	(411)	(210)
Effect of foreign exchange rate changes	(5)	(3)
Net Change in Cash	(323)	454
Beginning Balance	4,055	3,305
Ending Balance	3,732	3,759





Q&A





Appendix Company Overview



ScinoPharm at a Glance

- Est. in 1997 in Taiwan (Tainan) with cGMP plants/R&D in Tainan and Changshu and marketing forces in Tainan, Shanghai and Tokyo
- Specializes in high potency (cytotoxic/steroid) API and injectable R&D and manufacturing with customers worldwide
- 74 generic APIs in portfolio with 32 referred and approved by ANDA/NDA*
 - 875 active DMFs worldwide with 64 US DMFs*
- 150+ contract projects with 9 approved/launched (7 NCEs) and 6 in phase 3 for NDA/MAA filing in 1-3 years*
- Certified by key international regulators US FDA, EMA, EDQM, Australian TGA, Japanese PMDA, Korea KFDA, Mexico COFEPRIS and German Authority

* Data as of 2021/09/30





Brand Quality with Asian Advantages

www.scinopharm.com

1789 TT

